Publication details

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors	KYLE RA. DURIE BG. RAJKUMAR SV. LANDGREN O. BLADE J. MERLINI G. KRÖGER N. EINSELE H. VESOLE DH. DIMOPOULOS M. SAN MIGUEL J. AVET-LOISEAU H. HÁJEK Roman CHEN WM. ANDERSON KC. LUDWIG H. SONNEVELD P. PAVLOVSKY S. PALUMBO A. RICHARDSON PG. BARLOGIE B. GREIPP P. VESCIO R. TURESSON I. WESTIN J. BOCCADORO M.
Year of publication	2010
Type	Peer-reviewed scientific article
Magazine / Source	Leukemia
MU Faculty or unit	Faculty of Medicine
Citation
Doi	https://doi.org/10.1038/leu.2010.60
Field	Oncology and hematology
Keywords	Monoclonal gammopathy of undetermined significance; multiple myeloma
Description	Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years.